6-(4-oxo-cyclohexyl)-1H-pyridin-2-one | 1252689-91-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(4-oxo-cyclohexyl)-1H-pyridin-2-one
• 英文别名: 6-(4-oxocyclohexyl)-1H-pyridin-2-one
• CAS: 1252689-91-0
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: LQQRBECXGGNVJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(4-oxo-cyclohexyl)-1H-pyridin-2-one 、 N-(azetidin-3-ylcarbamoylmethyl)-3-trifluoromethyl-benzamide 生成 N-({1-[4-(6-oxo-1,6-dihydropyridin-2-yl)cyclohexyl]azetidin-3-ylcarbamoyl}methyl)-3-trifluoromethylbenzamide
  参考文献：
  名称：

  4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2

  摘要：

  本发明涉及式(I)的化合物，其中：X、R1、R2、R3和R4如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述的综合症、紊乱或疾病是2型糖尿病、肥胖症和哮喘。本发明还涉及一种通过给哺乳动物施用式(I)中至少一种化合物的治疗有效剂量来抑制CCR2活性的方法。

  公开号：

  US20100267688A1

文献信息

• 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2
  申请人：Janssen Pharmaceutica N.V.

  公开号：US08269015B2

  公开（公告）日：2012-09-18

  The present invention comprises compounds of Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涉及公式（I）的化合物，其中：X，R1，R2，R3和R4如规范中所定义。本发明还包括一种预防、治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是2型糖尿病、肥胖症和哮喘。本发明还包括一种通过给哺乳动物的C CR2活性抑制剂公式（I）的至少一种化合物治疗的方法。
• [EN] 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'OREXINE DE TYPE 3-AMINO PYRROLIDINE ET PIPÉRIDINE MACROCYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2022109117A1

  公开（公告）日：2022-05-27

  The present invention is directed to 3-amino pyrrolidine and piperidine macrocyclic compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及3-氨基吡咯烷和哌啶大环化合物，其为促进荷尔蒙受体的激动剂。本发明还涉及所述化合物在潜在的神经和精神障碍和疾病的治疗或预防中的用途，其中荷尔蒙受体参与其中。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗荷尔蒙受体参与的疾病中的用途。
• US8269015B2
  申请人：——

  公开号：US8269015B2

  公开（公告）日：2012-09-18
• [EN] 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2<br/>[FR] DÉRIVÉS DE 4-AZÉTIDINYL-1-HÉTÉROARYL-CYCLOHEXANE EN TANT QU'ANTAGONISTES DE CCR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010121011A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).